While GLP-1 drugs are effective at inducing weight loss, obesity remains a chronic condition thats difficult to manage long term, and weight regain is common once treatment ends without sustained dietary and lifestyle support
In this Review, we highlight recent preclinical studies using contemporary neuroscientific techniques that provide novel concepts in the neural control of food intake and body weight with reference to endogenous GLP-1, GLP-1R agonists, and bariatric surgery
Pattern 3: The Intolerant Switcher (approximately 25% of switchers) Develops moderate to severe nausea, vomiting, or diarrhea during tirzepatide titration Side effects persist beyond the typical 2-week adaptation window May tolerate 2.5 to 5 mg but cannot escalate to therapeutic doses (10+ mg) This pattern is more common in patients who had persistent but manageable GI side effects on semaglutide
Other symptoms may include headache, muscle pain, joint swelling, and a rash
Always speak with a licensed healthcare professional before starting, stopping, or changing any prescription medication or weight management plan
